Literature DB >> 34665673

Relative Prognostic Significance of Positron Emission Tomography Myocardial Perfusion Imaging Markers in Cardiomyopathy.

Merrill Thomas1,2, Brett W Sperry1,2, Poghni Peri-Okonny1,2, Ali O Malik1,2, A Iain McGhie1,2, Ibrahim M Saeed1,3,4, Paul S Chan1,2, John A Spertus1,2, Randall C Thompson1,2, Timothy M Bateman1,2, Krishna K Patel1,2.   

Abstract

BACKGROUND: Rubidium-82 positron emission tomography myocardial perfusion imaging provides measurements of perfusion, myocardial blood flow and reserve (MBFR), and changes in left ventricular ejection fraction (LVEF) at rest and peak stress. Although all of these variables are known to provide prognostic information, they have not been well studied in patients with heart failure due to reduced LVEF.
METHODS: Between 2010 and 2016, 1255 consecutive unique patients with LVEF≤40% were included in this study who underwent rubidium-82 positron emission tomography myocardial perfusion imaging and did not have subsequent revascularization within 90 days. Perfusion assessment was scored semiquantitatively, and LVEF reserve (stress-rest LVEF) and global MBFR (stress/rest MBF) were quantified using automated software. Cox proportional hazards models adjusted for 14 clinical and 7 test characteristics were used to define the independent prognostic significance of MBFR on all-cause mortality.
RESULTS: Of 1255 patients followed for a mean of 3.2 years, 454 (36.2%) died. After adjusting for clinical variables, the magnitude of fixed and reversible perfusion defects was prognostic of death (P=0.02 and 0.01, respectively), while the rest LVEF was not (P=0.18). The addition of LVEF reserve did not add any incremental value, while the addition of MBFR revealed incremental prognostic value (hazard ratio per 0.1 unit decrease in MBFR=1.08 [95% CI, 1.05-1.11], P<0.001) with fixed and reversible defects becoming nonsignificant (P=0.07 and 0.29, respectively). There was no interaction between MBFR and cause of cardiomyopathy (ischemic versus nonischemic).
CONCLUSIONS: In patients with a known cardiomyopathy who did not require early revascularization, reduced MBFR as obtained by positron emission tomography myocardial perfusion imaging is associated with all-cause mortality while other positron emission tomography myocardial perfusion imaging measures were not.

Entities:  

Keywords:  cardiomyopathies; myocardial perfusion imaging; positron emission tomography; prognosis; rubidium

Mesh:

Substances:

Year:  2021        PMID: 34665673      PMCID: PMC8555447          DOI: 10.1161/CIRCIMAGING.121.012426

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   8.589


  31 in total

1.  Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis.

Authors:  Sharmila Dorbala; Divya Vangala; John Bruyere; Christina Quarta; Jenna Kruger; Robert Padera; Courtney Foster; Michael Hanley; Marcelo F Di Carli; Rodney Falk
Journal:  JACC Heart Fail       Date:  2014-07-09       Impact factor: 12.035

2.  ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures.

Authors:  Vasken Dilsizian; Stephen L Bacharach; Rob S Beanlands; Steven R Bergmann; Dominique Delbeke; Sharmila Dorbala; Robert J Gropler; Juhani Knuuti; Heinrich R Schelbert; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2016-07-08       Impact factor: 5.952

3.  The Myocardial Interstitium: The Principal Therapeutic Target of the 21st Century?

Authors:  Erik B Schelbert; Y Chandrashekhar
Journal:  JACC Cardiovasc Imaging       Date:  2019-11

4.  Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction.

Authors:  Danilo Neglia; Claudio Michelassi; Maria Giovanna Trivieri; Gianmario Sambuceti; Assuero Giorgetti; Lorenza Pratali; Michela Gallopin; Piero Salvadori; Oreste Sorace; Clara Carpeggiani; Rosa Poddighe; Antonio L'Abbate; Oberdan Parodi
Journal:  Circulation       Date:  2002-01-15       Impact factor: 29.690

5.  Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy.

Authors:  Paco E Bravo; Stefan L Zimmerman; Hong-Chang Luo; Iraklis Pozios; Mahadevan Rajaram; Aurélio Pinheiro; Charles Steenbergen; Ihab R Kamel; Richard L Wahl; David A Bluemke; Frank M Bengel; M Roselle Abraham; Theodore P Abraham
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-15       Impact factor: 7.792

6.  Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease.

Authors:  Ankur Gupta; Viviany R Taqueti; Tim P van de Hoef; Navkaranbir S Bajaj; Paco E Bravo; Venkatesh L Murthy; Michael T Osborne; Sara B Seidelmann; Tomas Vita; Courtney F Bibbo; Meagan Harrington; Jon Hainer; Ornella Rimoldi; Sharmila Dorbala; Deepak L Bhatt; Ron Blankstein; Paolo G Camici; Marcelo F Di Carli
Journal:  Circulation       Date:  2017-09-01       Impact factor: 29.690

7.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

8.  Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure.

Authors:  Zhehao Dai; Tatsuo Aoki; Yoshihiro Fukumoto; Hiroaki Shimokawa
Journal:  J Cardiol       Date:  2012-08-04       Impact factor: 3.159

9.  Prognostic Value of Quantitative Metrics From Positron Emission Tomography in Ischemic Heart Failure.

Authors:  Dominik C Benz; Philippe A Kaufmann; Elia von Felten; Georgios Benetos; Georgios Rampidis; Michael Messerli; Andreas A Giannopoulos; Tobias A Fuchs; Christoph Gräni; Catherine Gebhard; Aju P Pazhenkottil; Andreas J Flammer; Philipp A Kaufmann; Ronny R Buechel
Journal:  JACC Cardiovasc Imaging       Date:  2020-08-05

Review 10.  Considerations for Clinical Trials Targeting the Myocardial Interstitium.

Authors:  Gavin A Lewis; Susanna Dodd; Josephine H Naish; Joseph B Selvanayagam; Marc R Dweck; Christopher A Miller
Journal:  JACC Cardiovasc Imaging       Date:  2019-08-14
View more
  1 in total

Review 1.  Coronary blood flow in heart failure: cause, consequence and bystander.

Authors:  Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2022-01-13       Impact factor: 12.416

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.